In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer PatientsMaria Vassilakopoulou, Amanda Psyrri, Urania Dafni et al.|PLoS ONE|2014Cited by 27